Espresso shot of the day – Caplin Point Laboratories Ltd up by 13.30 percent

EspressoLogy

Espresso shot of the day – Caplin Point Laboratories Ltd up by 13.30 percent

September 06, 2021
Espresso shot of the day – Caplin Point Laboratories Ltd up by 13.30 percent

CAPLIN POINT LABPORATORIES LTD 838.50 (+13.30%) BSE – INE475E01026 | 6TH SEPTEMBER 2021


Caplin Point was established in 1990 to manufacture a range of ointments, creams and other external applications. The company was listed in 1994 following its Initial Public Offering (IPO), which was oversubscribed 117 times, the proceeds of which were deployed in setting up a manufacturing facility at Pondicherry. Thereafter, the company expanded its product range and increased its production capacity. The company focused on the emerging markets of Latin America, Caribbean, Francophone countries and Southern Africa and is today one of the leading suppliers of pharmaceuticals in these regions, with over 2,800 product licenses across the globe. The company is entering into the regulated markets for Injectables through its state-of-the-art manufacturing facility, capable of handling Liquid Injectables in vials, ampoules, lyophilized vials and ophthalmic dosages. The facility is approved by US FDA, EU-GMP, ANVISA-Brazil and INVIMA-Colombia.

Recent Drivers

  • Caplin Steriles, a subsidiary of Caplin Point Laboratories, has received approval from Brazil's National Health Surveillance Agency, ANVISA, for its sterile injectables manufacturing site near Chennai, Tamil Nadu.
  • The company is also working on a portfolio of around 45 simple and complex injectables and ophthalmic products, which it intends to file over the next 4 years.
  • The company announced net sales at Rs 300.44 crores in June 2021, up 25.14% from Rs 240.08 crores in June 2020.
  • The company announced quarterly net profit at Rs 70.85 crores in June 2021, up 29.93% from Rs 54.53 crores in June 2020.
  • Caplin Point Laboratories announced final dividend of Rs 1.5 per equity share (75%). The record date of the dividend is Sept 29, 2021.
  • Caplin Steriles Limited has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Sumatriptan Injection USP, 6 mg/0.5 mL (12 mg/mL) single-dose vials. The product is a generic version of Imitrex injection of GlaxoSmithKline.
(Sources: Business Standard, Money Control, BSEIndia.com, Business World)

Technical Force*

  • S&P BSE 500 month till date gain up by 1.69%
  • 3 months avg. NSE volume: 5,92,954
  • Quantity traded: 1,17,833 | Deliverable quantity: 20,609 (17.49%)
  • Stock price has jumped more than 110% from one-year-low level: 402 (Mar 31, 2021)
  • Daily RSI (14) is in Oversold territory today
  • 52-week high: 1034 | 52-week low: 402

Key Pivot  (Yearly)

R4

R3

R2

R1

PP /FIB PP

S1

S2

S3

S4

Pivot Point

-

1241.33

963.37

735.53

457.67

229.33

-

-

    -

Fibonacci Pivot

963.37

770.37

650.96

574.05

457.67

341.29

264.37

144.96

    -


Today’s Close

838.50

SMA

BSE

10 DAY

743.65

20 DAY

782.70

50 DAY

768.00

200 DAY

574.57


Some Key Ratios (Source: BSE)

Market Cap: 6,342.64 crores

PE: 33.17

OPM%: 59.33

ROE%: 22.25

Promoters holding%: 69.03

Prev. Close: 740.05

*Chart And Technical Force data taken from the Binge desktop app.

The scope and usability of this information/data is time-sensitive and market-based, and as such the same may become outdated for the investment decisions of clients, for which Sharekhan comtrade bears no responsibility. References to securities do not constitute a recommendation to buy, sell or hold such securities. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document and should consult his own advisors to determine the merits and risks of such an investment. Sharekhan Comtrade Private Limited is under no obligation to update the information in this document from time-to-time.



Chandresh Khona
by Chandresh Khona

Product Offerings Head

A teacher, writer, travel buff and now Espresso's Product Offerings Head. Ten years here has allowed me to lead the digital team at Sharekhan. My true passion lies in stock market charts.